{"paper_id":"8b24f8a1-f773-4ef6-b7e3-a6c6ba63fac3","body_text":"Abstract\nPurpose\nThe aim of this study was to determine the autoimmune effects of ankylosing spondylitis (AS) on the fertility potential of women by evaluating ovarian reserves of AS patients.\nMethods\nA total of 104 patients, 52 in the AS group (study group) and 52 in the control group were included in the study. Ovarian reserve was evaluated by serum anti-Müllerian hormone (AMH) levels, antral follicle count (AFC) and baseline serum follicle-stimulating hormone (FSH) levels.\nResults\nThe mean serum AMH levels were significantly lower in the study group when compared to the controls (2.203 ± 1.110 vs. 1.188 ± 0.891, p < 0.001). In addition, the mean AFC was also significantly lower in the study group. (10.67 ± 1.81 vs. 9.54 ± 2.50, p = 0.009). Mean FSH levels were calculated to be 6.72 ± 1.14 in the study group and 7.21 ± 1.22 in the control group. The difference was not statistically significant (p = 0.781).\nConclusion\nThis study shows that AS like several other autoimmune conditions has an adverse effect on the female fertility potential. Therefore, an early start and long-term management of AS patients who have fertility desire is recommended. Serum AMH levels can be used in monitoring ovarian reserve and in early detection of reproductive decline of AS patients.\nClinicalTrial Number\nNCT04209881.\nSimilar content being viewed by others\nReferences\nBarbieri RL (2014) The endocrinology of the menstrual cycle. Methods Mol Biol 1154:145–169. https://doi.org/10.1007/978-1-4939-0659-8_7\nVannuccini S, Clifton VL, Fraser IS, Taylor HS, Critchley H, Giudice LC, Petraglia F (2016) Infertility and reproductive disorders: impact of hormonal and inflammatory mechanisms on pregnancy outcome. Human reproduction update 22(1):104–115\nCordts EB, Christofolini DM, dos Santos AA, Bianco B, Barbosa CP (2011) Genetic aspects of premature ovarian failure: a literature review. Arch Gynecol Obstet 283(3):635–643\nKomorowska B (2016) Autoimmune premature ovarian failure. Przeglad menopauzalny. Menopause Rev 15(4):210\nde Winter JJ, van Mens LJ, van der Heijde D, Landewé R, Baeten DL (2016) Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthrt Res Thera 18(1):196\nDean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ (2014) Global prevalence of ankylosing spondylitis. Rheumatology 53(4):650–657\nMohan MP, Ramesh TC (2003) Multiple autoimmune syndrome. Indian J Dermatol Venereol Leprol 69(4):298\nBrouwer J, Laven JS, Hazes JM, Schipper I, Dolhain RJ (2013) Levels of serum anti–Müllerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res 65(9):1534–1538\nŞahin A, Karakuş S, Durmaz Y, Yıldız Ç, Aydın H, Cengiz AK, Güler D (2015) Evaluation of ovarian reserve with anti-müllerian hormone in familial Mediterranean fever. International journal of rheumatology 5:3\ndel Carmen Velarde-Ochoa M, Esquivel-Valerio JA, Vega-Morales D, Skinner-Taylor CM, Galarza-Delgado DÁ, Garza-Elizondo MA (2015) Anti-Müllerian hormone in reproductive age women with systemic lupus erythematosus. Reumatología Clínica (English Edition) 11(2):78–82\nTuten A, Hatipoglu E, Oncul M, Imamoglu M, Acikgoz AS, Yilmaz N, Sahmay S (2014) Evaluation of ovarian reserve in Hashimoto’s thyroiditis. Gynecol Endocrinol 30(10):708–711\nKarakus S, Sahin A, Durmaz Y et al (2017) Evaluation of ovarian reserve using anti-müllerian hormone and antral follicle count in Sjögren's syndrome: preliminary study. J Obstet Gynaecol Res 43(2):303–307. https://doi.org/10.1111/jog.13216\nVural B, Cakiroglu Y, Vural F, Filiz S (2014) Hormonal and functional biomarkers in ovarian response. Arch Gynecol Obstet 289(6):1355–1361\nSilva CAA, Brunner HI (2007) Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus. Lupus 16(8):593–599\nFleming R, Seifer DB, Frattarelli JL, Ruman J (2015) Assessing ovarian response: antral follicle count versus anti-Müllerian hormone. Reproduct Biomed Online 31(4):486–496\nKarakus S, Sahin A, Durmaz Y, Aydin H, Yildiz C, Akkar O, Cetin A (2017) Evaluation of ovarian reserve using anti-müllerian hormone and antral follicle count in Sjögren's syndrome: preliminary study. J Obstet Gynaecol Res 43(2):303–307\nLinden SVD, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. Arthrit Rheum 27(4):361–368\nVignali M, Belloni GM, Pietropaolo G, Barbasetti Di Prun A, Barbera V, Angioni S, Pino I (2020) Effect of Dienogest therapy on the size of the endometrioma. Gynecol Endocrinol 1:1–5\nTomassetti C, D'Hooghe T (2018) Endometriosis and infertility: Insights into the causal link and management strategies. Best Pract Res Clin Obstet Gynaecol 51:25–33. https://doi.org/10.1016/j.bpobgyn.2018.06.002\nde Vet A, Laven J, de Jong F, Themmen A, Fauser B (2019) Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 112(4):E183–E188\nAnjum S, Zahra F, Yousuf SM (2019) Ovarian reserve parameters and response to controlled ovarian stimulation in infertile patients. Pak J Med Sci 35(4):958\nPractice Committee of the American Society for Reproductive Medicine (2015) Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril 103(3):e9–e17\nPorcu E, Cillo GM, Cipriani L, Sacilotto F, Notarangelo L, Damiano G, Roncarati I (2019) Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer. J Assist Reproduct Gene 1:1–7\nSchoemaker J, Drexhage H, Hoek A (1997) Premature ovarian failure and ovarian autoimmunity. Endocrine Rev 10:106–123\nSilva CA, Yamakami LYS, Aikawa NE, Araujo DB, Carvalho JF, Bonfá E (2014) Autoimmune primary ovarian insufficiency. Autoimmun Rev 13(4–5):427–430\nTapia-Serrano R, Jimenez-Balderas FJ, Murrieta S, Bravo-Gatica C, Guerra R, Mintz G (1991) Testicular function in active ankylosing spondylitis. Therapeutic response to human chorionic gonadotrophin. J Rheumatol 18(6):841–848\nGooren LJ, Giltay EJ, van Schaardenburg D, Dijkmans BA (2000) Gonadal and adrenal sex steroids in ankylosing spondylitis. Rheumatic Dis Clin North Am 26(4):969–987\nBrewerton DA, Hart FD, Nicholls A, Caffrey M, James DCO, Sturrock RD (1973) Ankylosing spondylitis and HL-A 27. The Lancet 301(7809):904–907\nCarter N, Williamson L, Kennedy LG, Brown MA, Wordsworth BP (2000) Susceptibility to ankylosing spondylitis. Rheumatology 39(4):445–445\nTaurog JD (2007) The mystery of HLA–B27: if it isn't one thing, it's another. Arthritis Rheum 56(8):2478–2481\nSen A, Kushnir VA, Barad DH, Gleicher N (2014) Endocrine autoimmune diseases and female infertility. Nat Rev Endocrinol 10(1):37\nYun BH, Kim G, Park SH, Noe EB, Seo SK, Cho S, Lee BS (2017) In vitro fertilization outcome in women with diminished ovarian reserve. Obstet Gynecol Sci 60(1):46–52\nFunding\nThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.\nAuthor information\nAuthors and Affiliations\nContributions\nPYB: study designation and manuscript writing; PK: manuscript writing and statistical analysis; BY: data interpretation; EÜÖ: laboratory analysis; KÇ: statistical analysis; NFTS: critically revised the article and supervised the study.\nCorresponding author\nEthics declarations\nConflict of interest\nThe authors have no conflict of interest to declare.\nEthics approval\nThe Institutional Review Board of Health Science University Istanbul Sadi Konuk Training and Research Hospital, Istanbul, Turkey approved this study (IRB Approval Number: 2019/456,).\nInformed consent\nInformed consent was obtained from all individual participants included in the study.\nAdditional information\nPublisher's Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nRights and permissions\nAbout this article\nCite this article\nYalçın Bahat, P., Kadiroğulları, P., Topbas Selcuki, N.F. et al. Ovarian reserve in patients with ankylosing spondylitis. Arch Gynecol Obstet 303, 189–193 (2021). https://doi.org/10.1007/s00404-020-05824-8\nReceived:\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s00404-020-05824-8","source_license":"CC0","license_restricted":false}